Clinical effect of Gefitinib(Iressa)in 51 cases of none-small cell lung cancer(NSCLC)
- VernacularTitle:吉非替尼治疗非小细胞肺癌51例疗效观察
- Author:
Xiaodong XIE
;
Zhendong ZHENG
;
Shuxian QU
- Publication Type:Journal Article
- Keywords:
Gefitinib;
Non-small cell lung cancer
- From:
Chinese Journal of Practical Internal Medicine
2006;0(16):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To ascertain clinical experience and toxic reactions of treating NSCLC by Gefitinib(Iressa).Methods Clinical data of 51 NSCLC cases were collected and analyzed who were treated with Iressa from Mar.2004 to Mar.2006.Evaluations were made about curative effects,quality of life,mean survival time,time to progression and toxic reactions.Results Fifty-one patients were all followed up.Total mitigative rate of the focus was 29.4%,total control rate was 66.7%,and alleviative rate of clinical symptoms was 62.7%.The difference of KPS grades in 4 weeks was significant.Mean survival time of all the patients was 8.2 months.Time to progression was 6.1 months.Ⅲ~Ⅳ grades of toxic reaction were not found.Conclusion Gefitinib may obviously improve the clinical symptom and QOL of the NSCLC patients,and it has good tolerance to treat NSCLC.It is a kind of molecule-target medicine suited with Chinese.
